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Introduction 
Epigenetic silencing mechanisms are increasingly thought to play a major role in the development of human 
cancers, including prostate cancer. The two major epigenetic regulatory mechanisms involve alterations in 
DNA methylation and histone acetylation status. Promoter CpG island hypermethylation and histone 
hypoacetylation, catalysed by DNA methyltransferase (DNMT) and histone deacetylase (HDAC) respectively, 
are associated with transcriptional repression. Evidence in other cancers suggests the two mechanisms are 
dynamically linked, yet few studies have examined the potential interaction of the two pathways in prostate 
cancer. Here we report a synergistic, apoptotic effect of treatment with a demethylating agent and a histone 
deacetylase inhibitor on cultured prostate cancer cells, with associated re-expression of the putative anti-
proliferative agent oestrogen receptor beta. 
 
Methods 
LNCaP, DU-145 and PC-3 cells were pre-treated with the DNMT inhibitor 5’-aza-2’-deoxycytidine (5-AZAC) 
for 72 hours followed by 24 hours combined treatment with 5-AZAC and the HDAC inhibitor trichostatin A 
(TSA). Following treatment, cells were either processed for cell proliferation, cell toxicity, cell viability and 
apoptosis assays, or harvested for quantitative real-time RT-PCR gene expression analyses. Assessed target 
genes were oestrogen receptor beta (ERβ), androgen receptor (AR), progesterone receptor (PGR) and prostate 
specific antigen (PSA). 
 
Results 
In all cell-lines co-treatment with 5-AZAC and TSA was associated with significantly reduced cell proliferation 
when compared with control groups (p<0.05); associated reduced cell viability and increased cell death 
was seen in all cases. Caspase activation was significantly increased in the co-treatment group, indicating that 
apoptosis was a major mechanism of cell death. Most marked effects were seen in the androgen-dependent, 
AR-positive LNCaP cell-line. In all cell-lines a marked synergistic re-expression of ERβ was identified in the 
co-treatment group, a finding which was not seen for either AR or PSA. A similar re-expression of PGR was 
also identified. 
 
Conclusions   
At concentrations associated with gene re-expression, the DNA demethylating agent 5-AZAC and the HDAC 
inhibitor TSA co-operate in an additive and synergistic way to induce apoptosis in prostate cancer cell-lines. 
Increased apoptosis in the co-treatment group was associated with marked re-expression of ERβ, which is an 
intriguing finding, raising the possibility of further targeting of prostate cancer cells with ERβ-selective agents 
such as phytooestrogens and selective oestrogen receptor modulators (SERMs). 
 
Introduction 
The regulation of gene expression in eukaryotes is complex and multilayered. Control may be exerted at the 
level of initiation of transcription, following transcription, or through epigenetic events. Epigenetic events are 
defined as alterations in gene expression without changes in the DNA coding sequence that are heritable 
through cell division (1), and are thought to be crucial in perpetuating tissue specificity. Two mechanisms are 
integral to epigenetic transcriptional control; DNA methylation and histone modification.  
 
DNA methylation, catalysed by DNA methyltransferase (DNMT), describes the addition of a methyl group to 
the cytosine residue of a CpG dinucleotide. The distribution of CpG dinucleotides in human genome is 
conspicuously restricted, except for certain CpG-rich ‘islands’, commonly located in the promoter region of 
approximately 60% of genes (2), which are typically unmethylated. Hypermethylation of CpG islands is 
associated with repression of downstream gene expression (3), possibly due to interference with the binding of 
transcription factors, or through the action of methylated DNA binding proteins (MBDs). Whilst DNA 
methylation is an important control mechanism in normal cells, inappropriate DNA methylation is thought to be 
important in the development of a majority of cancers, including prostate cancer. To date over 30 genes have 
been shown to be epigenetically silenced by hypermethylation in prostate cancer, including genes controlling 
cell cycle progression, tumour cell invasion, DNA repair, and hormonal response (4).  
 
ERβ is one such hormonal response gene known to be hypermethylated in prostate cancer. It contains a typical 
CpG island within its promoter (5), and has been shown to be re-expressed in prostate cancer cell-lines treated 
with DNMT inhibitors such as 5-aza-2’deoxycytidine (6-8). Furthermore, methylation-specific PCR studies 
have shown that the promoter region of the ERβ gene is hypermethylated in prostate cancer tissue studies (6, 8, 
9). The loss of ERβ in prostate cancer cell-lines and in tissue studies adds to an accumulating body of evidence 
supporting an antiproliferative role for ERβ in the prostate. For example, ERβ knockout mice (βERKO) 
develop severe epithelial hyperplasia in the ventral prostate, whereas no such abnormality is present in either 
ERα knockout mice or ERα/ERβ knockout mice (10, 11). ERβ also binds the cell cycle inhibitory protein, 
mitosis arrest deficient 2 (MAD2)(12), and antagonises ERα-mediated cyclin D1 expression (13), offering a 
potential mechanism for the regulation of cellular proliferation. An attenuation of androgen receptor activity 
has also been described (14). In βERKO mice AR is over-expressed in many tissues which normally express 
ERβ (15, 16), whereas genistein-mediated reduction in AR-expression in LNCaP cells is dependent upon ERβ 
(17). ERβ is also thought to confer protective effects on the cell by upregulating expression of anti-oxidative 
enzymes including quinone reductase and glutathione-S-reductase (14, 18), thereby protecting basal cells 
against oxidative damage, known to be a risk factor in neoplastic transformation. As the basal layer is thought 
to harbour progenitor cell populations responsible for cancer initiation and progression (19), and is also the site 
of strongest staining for ERβ (20, 21), it is possible ERβ exists to counter the proliferative and pro-oxidant 
actions of both ERα and AR. ERβ thus represents a potential novel target for therapeutic intervention in 
prostate cancer. 
 
The second mechanism of epigenetic transcriptional control results from histone modifications. Histones form  
the core around which double-stranded DNA is coiled to form a nucleosome. They are subject to a number of 
post-translational protein modifications, including acetylation, methylation, phosphorylation, and ubiquitination 
(22). Histone acetylation is associated with transcription activation, whereas deacetylation, catalysed by a 
family of histone deacetylases (HDACs), is associated with transcriptional silencing. Dysregulated epigenetic 
control of gene expression by histone modification is thought to be important in the development of a number 
of cancers, including prostate cancer (4). Typical abnormal findings in cancer cells include increased histone 
deacetylase activity (23) and associated transcriptional silencing of selected constitutive genes, including 
insulin-like factor growth factor-binding protein 3 (24) tissue inhibitor of matrix metalloproteinase (25), and 
carboxypeptidase A3 (26). To our knowledge there have been no reports to date documenting a similar effect 
on ERβ expression in prostate cancer cells.    
 
Although histone modification and DNA methylation are both independent processes, they are also integrally 
linked (27). For example DNA methyltransferases are known to independently recruit histone deacetylases, 
leading to histone deacetylation and transcriptional repression (28, 29). In addition, MBDs can independently 
recruit HDACs to the site of DNA methylation (3, 30). A number of in vitro studies have demonstrated that 
DNA methylation and histone deacetylation may co-operate to repress gene transcription (31-33). In addition, 
the combination of HDAC and DNMT inhibition has also been shown to induce apoptosis, differentiation 
and/or cell growth arrest in human lung, breast, thoracic, leukemia and colon cancer cell-lines (34). To our 
knowledge there have been no reports to date documenting the effects of combination therapy in prostate 
cancer cell-lines. 
Methods 
 
Cell-culture 
DU-145, LNCaP, and PC-3 prostate cancer cell-lines were purchased from the American Type Culture 
Collection (ATCC). DU-145 cells were grown in Dulbecco’s Modified Eagle’s Medium (Cambrex Bioscience 
Ltd.), LNCaP cells were grown in RPMI 1640 Medium (Cambrex) and PC-3 cells were grown in Nutrient 
Mixture F-12 Ham medium (Sigma-Aldrich Company Ltd.). All cells were grown in media supplemented with 
10% foetal calf serum (Cambrex) and 2 mM L-glutamine, and were incubated at 37°C in an atmosphere 
containing 5% CO2.  
 
Cell-culture treatment with TSA and 5-AZAC 
Following optimisation, prostate cancer cells were pre-treated with the DNMT inhibitor 5’-aza-2’-
deoxycytidine (5-AZAC), followed by the addition of the HDAC inhibitor trichostatin A (TSA). On day 0, 
equal numbers of cells were seeded into 16 identical culture vessels (flasks or wells). For 25 cm2 culture flasks 
1 x 105 cells were seeded in 10 mls of media; for 96-well plates, 2000 cells were seeded in 100 μl of media per 
well. Cells were allowed to seed overnight. The following day (day 1) quadruplicates were assigned to control, 
TSA only, 5-AZAC only, and TSA and 5-AZAC (T&A) treatment groups. 5-AZAC (Sigma-Aldrich) dissolved 
in Dulbecco’s Phosphate Buffered Saline (DPBS, Cambrex) was added to 5-AZAC and T&A assigned flasks at 
a final working concentration of 8.8 μM. An equivalent volume of DPBS was added to control and TSA flasks. 
Flasks were left for 72 hours. After 72 hours (day 4) trichostatin A (Sigma-Aldrich) dissolved in ethanol was 
added to TSA and T&A assigned flasks at a final working concentration of 300 nM. An equal volume of 
ethanol was added to control and 5-AZAC flasks. After a further 24 hours (day 5) cells were harvested for 
RNA/protein extraction, or used for cell proliferation/apoptosis assays. 
  
Tritiated thymidine proliferation assay 
[3H]-thymidine (Amersham Biosciences UK Ltd.) was added to cells grown in a 96-well plate at a final 
concentration of 0.037 MBq/ml 16 to 18 hours prior to cell harvesting. Cells were harvested onto a 96-well 
Unifilter™ GF/C microplate (Perkin Elmer UK Ltd.) and the plate was left to dry for 1 hour at 37 °C. 40 μl of 
Microscint-O™ scintillin (Perkin Elmer) was added to each well and the plates were counted on a TopCount 
NXT™ microplate scintillometer. 
 
 
Cytotoxicity, cell-viability and apoptosis assays 
The Toxilight™  cytotoxicity assay (Cambrex) detects adenylate kinase, which leaks from cells in the terminal 
stages of cell death. The Vialight™ Plus assay (Cambrex) measures abundance of cellular adenosine 
triphosphate (ATP), which is a marker for cell viability. The Caspase-Glo™ 3/7 apoptosis assay (Promega UK 
Ltd.) measures levels of caspases 3 and 7, which are key effectors of apoptosis in humans. Cells were grown in 
white-walled, clear-bottomed 96-well tissue culture plates (Lumitrac™ 200, Jencons Scientific Ltd.) to reduce 
light contamination between wells. Quadruplicate blank wells were included containing assay reagent, vehicle, 
and cell-culture medium without cells to control for background luminescence. For the Toxilight™ assay, a 
further set of control quadruplicates was incorporated to assess luminescence following 100% lysis using the 
ToxiLight™ 100% Lysis Reagent Set. Following addition of respective Toxilight™ and Vialight™ reagents, 
bioluminescence was measured after 5 mins on a PlateLumino™ luminometer (Stratec Biomedical Systems). 
For apoptosis assays Caspase-Glo™ reagents were mixed and added to the microplate, agitated for 30s, 
wrapped in foil and incubated at room temperature for 90 mins before determination of luminescence. Relative 
luminescence (RLU) was expressed as average assay luminescence minus average background fluorescence. 
 
RNA isolation and reverse transcription (RT) 
An RNeasy™ Mini Kit (Qiagen Ltd.) was used to isolate RNA from cell-lines for real-time RT-PCR. Prior to 
RNA extraction, cell lysates were homogenised using a QIAshredder™ (Qiagen), centrifuged at 14,000g for 2 
mins. The homogenate was added to an RNeasy® spin column and the protocol for animal tissues was followed, 
including an on-column RNase-free DNase step (Qiagen). Isolated RNA was reverse transcribed as follows: 
2 µg of RNA was added to an Eppendorf tube along with 0.5 µg of oligo(dT)15 primer (Promega). The tube was 
heated at 70°C for 5 minutes and immediately placed on ice. 5 µl M-MLV 5x reaction buffer, 1 µl dNTPs 
(12.5 mM, Bioline Ltd.), 25 units RNasin® ribonuclease inhibitor (Promega), and 200 units M-MLV reverse 
transcriptase (Promega) was added along with RNase-free water (Sigma-Aldrich) to a final volume of 25 µl. 
The contents of the tube were mixed gently and incubated at 39ºC for 80 minutes, following which the tube was 
heated at 95°C for 5 mins to inactivate the reverse transcriptase.  
 
Real-time RT-PCR 
Real-time RT-PCR reactions were performed on an Mx4000 Quantitative PCR System (Stratagene Inc.). Prior 
to thermocycling total cDNA concentration of standards and specimens was determined using a NanoDrop® 
ND-1000 UV spectrophotometer (Nanodrop Technologies). Thermocycling was done in 0.2 ml optical PCR 
strip tubes containing 12.5 μl of QuantiTect™ SYBR® green master mix (Qiagen), 2 μl of gene-specific 
forward and reverse primers, and 8.5 μl of RNase-free water (Qiagen), to which 2 μl of template cDNA was 
added. Each specimen assay was performed in duplicate. Common PCR reaction conditions were as follows:  
94°C  for  5  mins; 95°C  for  30  s;  n °C  for  30 s;  72°C for 30 s: cycling through denaturation, annealing and 
extension for x cycles; 72°C for 5mins. Gene-specific primer sequences, annealing temperatures (n) and cycle 
numbers (x) are shown in Table 1. All primers were designed for real time RT-PCR, and all except ribosome 
h18S were intron-spanning. Two housekeeping genes were used; ribosome h18S (h18S) and glucose-6-
phosphate dehydrogenase (GAPDH). Mean specimen starting template RNA concentration was determined 
from constructed calibration curves. Derived target gene expression was normalised by expression relative to 
individual housekeeping gene expression. 
 
SDS-PAGE and Western Blotting 
Protein lysates were obtained using standard techniques. 30 mg of reduced protein sample was loaded into each 
well of a 10% polyacrylamide gel and submerged in SDS running buffer. Electrophoresis was performed at 
100V for approximately 90 mins. Proteins were transferred onto a nitrocellulose membrane over 45 minutes at 
13V. After overnight incubation in 5% milk protein/TBS-Tween (TBST), either 1:1000 monoclonal mouse 
anti-α-tubulin antibody (T6199, Sigma-Aldrich) or 1:1000 polyclonal goat anti-ERβ antibody (sc-6820, Santa 
Cruz Biotechnologies, Inc.) was added to one of duplicate membranes containing specimen samples and 
incubated for 3 hours at room temperature. Appropriate secondary antibodies (DakoCytomation Ltd.) were 
added at a dilution of 1:1000 in 5% milk protein/TBST and incubated for 2 hours at room temperature. Protein 
expression was determined using the ECL™ Western Blotting Detection Kit (Amersham). 
 
Statistical analyses 
All statistical analyses were performed using SPSS statistical software (version 11.5, SPSS Inc.) Where 
continuous data was normally distributed, means were compared by independent samples t-test. Non-
parametric continuous data was analysed using the Mann-Whitney U test. Correlation between two 
continuously distributed variables was assessed using logistic regression for parametric data and Spearman’s 
correlation coefficient for non-parametric data. 
 
 
 
Results 
 
DNA demethylation and HDAC inhibition is associated with reduced proliferation, increased cell death and 
apoptosis in prostate cancer cell-lines 
Proliferation following treatment of DU-145, LNCaP and PC-3 cells with 5-AZAC and TSA was determined 
by tritiated thymidine proliferation assay. The results are shown in Fig. 1. TSA and 5-AZAC were 
independently associated with reductions in cell proliferation when compared with the control group in all three 
prostate cancer cell-lines. Of the two drugs 5-AZAC was more potent in inhibiting cell-proliferation in all cell-
lines tested. Co-treatment with TSA and 5-AZAC was associated with values for cell proliferation which were 
significantly reduced compared with those obtained for TSA treatment or 5-AZAC treatment alone (p<0.001 
for DU-145 and LNCaP; p<0.05 for PC-3) indicating a synergistic effect for co-administration. 
 
Reduced cell proliferation following drug treatment results from either an inhibition of cell growth/division, 
cell death, or a combination of the two mechanisms. We used the complementary Vialight® and Toxilight® 
assays to assess the degree of cell viability and cell toxicity respectively in prostate cancer lines treated with 
TSA and 5-AZAC. The results are shown in Fig. 2. In all cell-lines TSA and 5-AZAC were independently 
associated with reduced cell viability compared with the control group. In PC-3 cells, 5-AZAC treatment was 
associated with a significantly greater reduction in cell viability than was seen for TSA treatment (p<0.001). 
There was no significant difference between the drugs in either DU-145 or LNCaP cells. For all cell-lines co-
treatment was associated with significantly reduced cell viability compared with the more effective single-agent 
treatment (p<0.0001 for DU-145 and LNCaP cells; p<0.001 for PC-3 cells). In terms of magnitude of effect, 
when compared with the control group, co-treatment was associated with mean reductions in cell viability of 
93.3%, 82.3%, and 68.0% for DU-145, LNCaP, and PC-3 cells respectively. 
 
Reduced cell viability usually implies cell death. Toxilight® assays confirmed a broadly reciprocal relationship 
between cell viability and cell death for all cell-lines. In LNCaP and PC-3 cell-lines co-treatment with TSA and 
5-AZAC was associated with significant increases in cell death compared with the more effective single agent  
(p<0.001 each). Interestingly in DU-145 cells co-treatment did not produce any additional cytotoxic effect over 
TSA treatment alone. The reasons for this are unclear. Cytotoxicity was greatest in AR-positive LNCaP cells. 
When assessed relative to 100% lysis, co-treatment in LNCaP cells was associated with mean cell death of 
84.7%, compared with 33.1% and 47.8% for DU-145 and PC-3 cells respectively. The similar values obtained 
for reduced cell viability and increased cell death in LNCaP cells suggest that the reduced proliferation seen 
with co-treatment is primarily a function of cell-death. In DU-145 and PC-3 cells however the values are less 
concordant, suggesting that impaired growth and cytotoxicity contribute to reduced proliferation. 
 
Visual inspection of cells following drug treatment showed that in addition to reduced numbers, cells changed 
morphology, particularly following co-administration of both drugs. Typical changes included cell membrane 
cell shrinkage and membrane blebbing, consistent with apoptosis. Changes were most marked in LNCaP cells 
(Fig. 3). This initial impression was confirmed by caspase 3/7 apoptosis assay. As shown in Fig. 4, treatment 
with TSA and 5-AZAC was associated with increases in mean caspase 3/7 activation when compared with 
control cells in DU-145, LNCaP and PC-3 cells; for TSA treatment the differences were significant in DU-145 
and LNCaP cells (p<0.001); for 5-AZAC treatment the differences were significant in all three cell-lines 
(p<0.001). As was seen for the cytotoxicity assays, co-treatment did not produce an additional apoptotic effect 
in DU-145 cells when compared with TSA treatment alone. In LNCaP and PC-3 cells however, co-treatment 
was associated with significant increases in apoptotic activity compared with the more effective single agent 
(p<0.001 for LNCaP and PC-3). The greatest magnitude of response following co-treatment was again seen in 
LNCaP cells. When compared with the control group, co-treatment induced an 11.5-fold increase in apoptotic 
activity in LNCaP cells, compared with 7.5-fold and 1.5-fold increases in DU-145 and PC-3 cells respectively. 
  
DNA demethylation and HDAC inhibition is associated with re-expresssion of ERβ in prostate cancer cell-lines 
Ribosome h18S-normalised gene expression for ERβ, AR, ERα, PSA and PGR is shown in Fig. 5. Very similar 
results were obtained for the GAPDH housekeeping gene (data not shown). This finding, along with the 
demonstration of strong positive correlations between ERα and ERα-dependent PGR (p<0.001), and AR and 
AR-dependent PSA (p<0.001), supports the validity of obtained results.  
 
Co-treatment was associated with ERβ re-expression in all cell-lines tested. When compared with the control 
group however, results were non-significant in PC-3 and DU-145 cells, although in the latter case the results 
just failed to achieve statistical significance (p=0.06). The results were significant in androgen-responsive 
LNCaP cells (p<0.05). Interestingly, 5-AZAC treatment failed to cause re-expression of ERβ in this cell-line 
suggesting that chromatin remodelling and not DNA methylation was the primary mechanism of gene 
silencing. However, co-treatment did increase ERβ expression over TSA treatment alone, suggesting an 
additional co-stimulatory effect of 5-AZAC. Similar results are seen for ERβ protein expression (Fig 6). 
Allowing for unavoidable low level non-specific contamination, clearly identifiable in the secondary-only lane, 
TSA treatment and to a lesser extent 5-AZAC treatment were associated with a re-expression of ERβ protein. 
As seen with ERβ gene expression, combination therapy was associated with the most marked re-expression of 
ERβ protein.  
 
The results obtained for androgen receptor were intriguing. In the androgen-independent AR-negative DU-145 
and PC-3 cell-lines, co-treatment with TSA and AZAC caused a marked re-expression of AR which achieved 
significance in the DU-145 cell-line (p<0.01). Very little re-expression of AR was seen following single 
treatment with either TSA or 5-AZAC. In contrast, TSA treatment induced a reduction in AR expression in 
LNCaP cells lines without any additional additive effect following 5-AZAC administration. Whilst the results 
for AR did not achieve statistical significance, results for androgen-dependent PSA – which exactly mirrored 
those of AR – were significant (p<0.001). There initially appeared to be a reciprocal relationship in ERβ and 
AR expression. However, pairwise correlation analyses failed to identify a significant relationship between the 
genes.  
 
The expression of ERα following co-treatment with TSA and 5-AZAC was very similar to that of ERβ. LNCaP 
cells, TSA was more effective than 5-AZAC in causing ERα re-expression. Co-treatment with the drugs 
produced the most marked effect. Levels of ERα-dependent PGR were also re-expressed following co-
treatment and closely mirrored those of ERα. Pairwise correlation analyses confirmed a strong positive 
association between the genes (p<0.001). 
Discussion 
A number of studies have reported reductions in cell proliferation and apoptosis in prostate cancer cell-lines 
treated with HDAC inhibitors (25, 35-39). Fronsdal et al investigated the response of DU-145 LNCaP and PC3 
cells to a number of HDAC inhibitors, including trichostatin A. Treatment with 100 nM TSA resulted in 
approximate increases cell death of 10% over control cells in DU-145 and LNCaP cells. PC-3 cells however 
were largely resistant to HDAC treatment. In this study TSA treatment with 300 nM TSA produced a larger 
increase in cell death in DU-145 cells (~28%), with a similar increase in LNCaP cells (~10%), whilst PC-3 cells 
were also found to be generally resistant. The reasons for the differences are unclear, but may relate to different 
cell-culture conditions, treatment regimens, and drug vehicles used. Fronsdal’s group also used the relatively 
inaccurate trypan blue exclusion assay to determine cell death rates, whereas we utilised a highly sensitive 
bioluminescent method. Whilst a small number of studies have reported inhibited cell proliferation and 
induction of apoptosis in prostate cancer cell-lines following 5-AZAC treatment (40), the majority report 
changes in gene expression associated with demethylation without mention of major effects on cell 
proliferation. The drug dosage used in this study approximates that associated with altered gene expression, yet 
in this study 5-AZAC administration was associated with significantly reduced proliferation in all cell-lines 
when compared with controls. Interestingly, relatively modest cytotoxicity (<7.5%) and apoptotic activity was 
observed in the 5-AZAC treatment group, suggesting that 5-AZAC mediated changes in gene expression reduce 
cellular proliferation by impairing cell growth and division rather than by initiating  apoptosis. This is in 
contrast to the study by Pulukuri et al who identified activation of p53 and p21WAF1/CIP and subsequent marked 
upregulation in apoptosis following treatment of LNCaP cells with 5-AZAC. 
  
The combination of HDAC and DNMT inhibition has been shown to induce apoptosis, differentiation and/or 
cell growth arrest in human lung, breast, thoracic, leukaemia and colon cancer cell-lines (34), but to date no 
studies have identified a similar relationship in prostate cancer cell-lines. In the data presented herein it is 
shown for the first time that co-treatment with TSA and 5-AZAC inhibits cell growth and induces apoptosis of 
prostate cancer cells. In androgen-dependent LNCaP cells a truly synergistic effect was identified, particularly 
for apoptosis, whereas for androgen-independent DU-145 and PC-3 cells the effects were additive. The findings 
suggest that combination treatment may have a role in the treatment of advanced prostate cancer, particularly as 
recent clinical trials of 5-AZAC (also known as decitabine) in metastatic prostate cancer have been 
disappointing (41, 42). In a phase II study reported by Thibault et al, only 2 of 12 men with androgen 
independent metastatic prostate cancer treated with decitabine developed a clinical response leading to delayed 
progression. The authors concluded that the low-dose decitabine regime was well-tolerated with a modest 
clinical activity. Although a number of HDAC inhibitors have shown promising antitumour activity in animal 
models of prostate cancer (36, 43, 44), as yet there are no published clinical trials in humans. A number of 
phase I trials have however reported good clinical efficacy and a favourable side-effect profile for HDAC 
inhibitors in a range of other solid and haematological malignancies (45). It is thus tempting to speculate that 
combination therapy with HDAC and DNMT inhibitors may improve response rates in prostate cancer over that 
seen with DNMT inhibitors alone.  
 
In addition to reduced cell proliferation and induction of apoptosis, we have been shown that combination 
therapy with TSA and 5-AZAC upregulates the expression of ERβ mRNA and protein in prostate cancer cell-
lines. In all cell-lines assessed there was a synergistic effect of combination therapy, which achieved statistical 
significance in LNCaP cells. It therefore seems likely that histone acetylation and DNA methylation co-operate 
to epigenetically silence ERβ in prostate cancer. Although we cannot definitively state this to be true without 
assessing histone acetylation status and DNA methylation status of the ERβ promoter before and after co-
treatment, the observation of similar effects in other studies suggest that this is likely to be the case (34). This 
finding contributes to the accumulating data identifying layering of epigenetic silencing in prostate cancer. 
Cameron et al first reported an additive effect for HDAC and DNMT inhibitors in the re-expression of a 
number of genes silenced in colon cancer, including TIMP3 (31). Since then multiple studies have identified a 
similar relationship for a variety of genes in breast cancer (46-48), lung cancer (49), lymphosarcoma (50) and 
prostate cancer (32, 33). Interestingly in the study by Nakayama, co-treatment with TSA and all-trans retinoic 
acid after treatment with 5-AZAC resulted in re-expression of androgen receptor in DU-145 cells, which 
corroborates the results presented in this study. 
 
Although ERβ is thought to have anti-proliferative actions in the prostate, the reduced proliferation and 
apoptosis seen with co-treatment in this study is unlikely to be due to ERβ re-expression alone, given the 
tendency of HDAC and DNMT inhibitors to preferentially release tumour suppressor and pro-apoptotic genes 
from epigenetic silencing. The finding does however warrant further investigation. Recent evidence also 
suggests that upregulation of ERβ may act to inhibit migration of prostate cancer cells. Guerini et al have 
shown that stimulation of ERβ with the androgen derative 5alpha-androstane-3beta,17beta-diol (3betaAdiol) 
results in an inhibition of prostate cancer cell migration (51). The mechanism of action is thought to involve 
upregulation of E-cadherin expression. Thus upregulation of ERβ expression following DNMT and HDAC 
inhibition may therefore provide a target for subsequent ligand activation with 3beta-Adiol. A number of 
studies have also identified novel therapeutic agents which target ERβ in prostate cancer and are reported to 
induce apoptosis in prostate cancer cell-lines (17, 52). Thus in a similar way upregulation of ERβ following co-
treatment may sensitise prostate cancer cells to subsequent treatment with conventional oestrogens and newer 
agents such as phytooestrogens and selective oestrogen receptor modulators (SERMs).  
 
The results obtained for androgen receptor are intriguing. In androgen receptor negative DU-145 and PC-3 
cells, DNMT and HDAC inhibition was associated with a re-expression of androgen receptor, implying 
epigenetic silencing in these cell-lines. In androgen-receptor positive LNCaP cells however, co-treatment was 
associated with a significant reduction in androgen-receptor expression. The mechanism of reduced gene 
expression following HDAC and DNMT inhibition is unclear. Reduced AR expression was predominantly 
associated with TSA administration, as shown in Fig. 5, yet HDAC inhibitors – including TSA – are reported to 
maximise AR expression in LNCaP cells (53). The reason for the discrepancy between our findings and those 
of Korkmaz are unclear, but may to relate to the latter group’s pre-treatment of LNCaP cells with the synthetic 
androgen R1881 prior to HDAC inhibition (53). It remains possible that the reduced expression of AR observed 
following co-treatment is dependent upon the upregulation of a putative inhibitor of AR-transcription. Although 
ERβ has been postulated as an inhibitor of AR function in LNCaP cells, (17), pair-wise analyses failed to 
confirm the presence of a significant negative correlation between the genes. 
 
Traditionally, AR positive, androgen-reponsive LNCaP cells have been used as a model for androgen-
dependent prostate cancer, whereas AR negative DU-145 and PC-3 cells have been used as a model for 
androgen-independent disease. However, it is now known that the majority of metastatic deposits of prostate 
cancer continue to express androgen receptor (54-56), and current theories of androgen independence have 
focussed on the presence of a functioning androgen receptor (i.e. AR hypersensitivity, promiscuity, 
amplification etc.) (57). In addition androgen-independent clones of LNCaP (LNCaP-abl and AI:LNCaP) have 
been developed which are associated with upregulated AR expression and higher levels of AR reporter gene 
activity, indicating preserved androgen pathway function (58). For these reasons the validity of AR-negative 
DU-145 and PC-3 cells as a model for androgen-independent disease has been questioned, and it is believed 
that of the three-cell-lines used in this study, LNCaP represents the most appropriate model for advanced 
prostate cancer.  
 
The combination of reduced AR expression and upregulated ERβ expression in LNCaP cells following co-
treatment suggests conversion to a more favourable phenotype in prostate cancer. ERβ is associated with 
antiproliferative and potentially anti-migratory actions in prostate cancer cells. Reduced AR expression induced 
by antisense oligonucleotides is also associated with an inhibition of proliferation in LNCaP cells (59). The role 
of upregulated ERα and PGR expression following co-treatment is less clear. Although ERα is thought to be 
associated with prostate carcinogenesis the effects of its re-expression in established prostate cancer are 
unknown. Likewise, although PGR expression is known to be down-regulated in prostate cancer (60, 61), the 
role of PGR re-expression is similarly undefined. Nevertheless combination therapy with TSA and 5-AZAC 
induces a spectrum of genotypic changes which are associated with the development of a favourable phenotype, 
marked reductions in cell proliferation and increased apoptosis in LNCaP cells. 
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Figure 1  3[H]-thymidine uptake following treatment with TSA and 5-AZAC in prostate cancer cell-lines 
In all cell-lines single-drug treatment was associated with a reduction in cell proliferation, with 5-AZAC 
displaying a greater magnitude of effect than TSA in all cases. Co-treatment was associated with significant 
reductions in cell proliferation than single-drug therapy (5-AZAC) for all cell lines (p<0.001 for LNCaP and PC-
3; p<0.05 for DU-145). 
 
Figure 2  Cell viability and cytotoxicity following treatment with TSA and 5-AZAC in prostate cancer cell-lines 
In all cell-lines single-drug treatment was associated with reduced cell viability. When TSA and 5-AZAC were 
compared, TSA induced a greater reduction in cell viability in DU-145 cells, whereas 5-AZAC was more potent in 
LNCaP and PC-3 cells. In all three cell-lines co-treatment was associated with significant falls in cell viability 
compared with the more effective single-drug treatment (p<0.0001 for DU-145 and LNCaP cells; p<0.001 for PC-3 
cells). Co-treatment was also associated with significantly greater cytotoxicity in LNCaP and PC-3 cells when 
compared with the more effective single agent (p<0.001 and p<0.05 respectively). For DU-145 cells however TSA 
treatment appeared to be the main agent responsible for cell death 
    
Figure 3  Visual appearance of LNCaP cells following treatment with TSA and 5-AZAC (Day 5) 
In the control group there were high numbers of small confluent cells with few dead cells. Following TSA 
treatment, cell proliferation was reduced with a higher proportion of dead cells; cells were also larger and less 
confluent. Similar but less striking appearances were seen following 5-AZAC treatment. Combination treatment 
resulted in a further reduction in cell proliferation with a corresponding increase in dead cells. Commonly, the 
remaining  adherent cells showed characteristic features of a apoptosis including cell shrinkage and membrane 
blebbing (arrowed).  
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Figure 4  Apoptosis following treatment with TSA and 5-AZAC in prostate cancer cell-lines (day 5) 
In all cell lines single-drug treatment was associated with increased apoptotic activity compared with the control 
group; both drugs achieved statistical significance in DU-145 and LNCaP cells (p<0.001), whereas only 5-AZAC 
treatment achieved significance in PC-3 cells. In DU-145 and LNCaP cells co-treatment was associated with 
significantly increased apoptotic activity when compared with the most effective single-drug treatment (p<0.001). 
In DU-145 cells however, there was no additional benefit of co-treatment over that of TSA alone.  
Figure 6  ERβ protein expression in LNCaP prostate cancer cells following 5-AZAC and TSA treatment 
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Figure 5  Selected ribosome h18S-normalised gene expression following co-treatment with TSA and 5-AZAC in prostate cancer cell-lines (Day 5) 
Expression levels of ERβ increased in all three cell-lines following drug treatment, although when control and co-treatment groups were compared differences were only significant in LNCaP cells (p<0.05). A 
similar increase in DU-145 cells just failed to achieve statistical significance (p=0.06). Results obtained for AR and PSA were divergent for androgen-dependent AR-positive LNCaP cells, and androgen-
independent AR-negative DU-145 and PC-3 cells. In the latter case, co-treatment was associated with increased AR expression, which achieved significance in DU-145 cells (p<0.01). In LNCaP cells co-
treatment was associated with a reduction in AR expression which failed to reach significance. A significant reduction was demonstrated for AR-dependent PSA expression (p<0.001) however, which showed 
strong positive correlation with AR expression (P<0.001). In all cell-lines ERα expression increased with co-treatment, achieving significance in DU-145 and LNCaP cells (p<0.05) when compared with the 
control group. In LNCaP cells TSA treatment was associated with greater ERα re-expression than was seen following 5-AZAC treatment. Results obtained for ERα and PGR were closely related for all cell-
lines, as confirmed by a significant positive relationship following pairwise correlation analysis (p<0.001).  
 
 
